LFST RSI Chart
Last 7 days
-10.5%
Last 30 days
-11.5%
Last 90 days
-15.6%
Trailing 12 Months
-25.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 909.0M | 959.1M | 1.0B | 1.1B |
2022 | 727.5M | 776.5M | 820.2M | 859.5M |
2021 | 408.7M | 523.8M | 595.6M | 667.5M |
2020 | 0 | 253.7M | 336.0M | 377.2M |
2019 | 0 | 0 | 0 | 212.5M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 15, 2024 | burdick kenneth a | sold | -1,347,720 | 6.28 | -214,605 | chief executive officer |
Mar 14, 2024 | pardo ryan | sold | -249,301 | 6.33 | -39,384 | see remarks |
Mar 14, 2024 | mullins kevin michael | sold | -281,938 | 6.33 | -44,540 | chief development officer |
Mar 13, 2024 | qureshi danish j. | sold | -972,920 | 6.32 | -153,943 | see remarks |
Mar 12, 2024 | pantaleoni pablo | sold | -292,735 | 6.76 | -43,304 | chief digital officer |
Mar 11, 2024 | cipollone paula | sold | -96,992 | 6.93 | -13,996 | see remarks |
Mar 11, 2024 | bourdon david | sold | -407,664 | 6.93 | -58,826 | chief financial officer |
Mar 11, 2024 | varanakis ann | sold | -106,958 | 6.93 | -15,434 | chief people officer |
Mar 08, 2024 | mullins kevin michael | acquired | - | - | 214,412 | chief development officer |
Mar 08, 2024 | bourdon david | acquired | - | - | 228,666 | chief financial officer |
Which funds bought or sold LFST recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 16, 2024 | Stratos Wealth Partners, LTD. | sold off | -100 | -93,498 | - | -% |
Apr 15, 2024 | Sunbelt Securities, Inc. | unchanged | - | -7,304 | 27,148 | -% |
Apr 12, 2024 | AdvisorNet Financial, Inc | sold off | -100 | -16.00 | - | -% |
Apr 05, 2024 | GAMMA Investing LLC | added | 1,200 | 148 | 160 | -% |
Apr 05, 2024 | CWM, LLC | sold off | -100 | -3,000 | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 0.65 | 7,604,520 | 59,302,600 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 569 | 14,651,600 | 16,860,300 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.4 | 49,182 | 413,079 | -% |
Feb 16, 2024 | CIM INVESTMENT MANAGEMENT INC | unchanged | - | 15,080 | 122,994 | 0.04% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 5.41 | 50,000 | 296,000 | -% |
Unveiling LifeStance Health Group, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to LifeStance Health Group, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 432.4B | 371.6B | 19.32 | 1.16 | ||||
CI | 101.4B | 195.3B | 18.87 | 0.52 | ||||
CVS | 86.8B | 357.8B | 10.4 | 0.24 | ||||
HCA | 83.0B | 65.0B | 15.84 | 1.28 | ||||
CNC | 38.7B | 154.0B | 14.31 | 0.25 | ||||
DVA | 11.4B | 12.1B | 16.46 | 0.94 | ||||
UHS | 11.2B | 14.3B | 15.59 | 0.78 | ||||
MID-CAP | ||||||||
CHE | 9.2B | 2.3B | 33.75 | 4.06 | ||||
ACHC | 6.5B | 2.9B | -302.25 | 2.24 | ||||
AMN | 2.2B | 3.8B | 10.21 | 0.57 | ||||
AMEH | 2.1B | 1.4B | 34.59 | 1.51 | ||||
SMALL-CAP | ||||||||
ADUS | 1.6B | 1.1B | 25.15 | 1.48 | ||||
BKD | 1.2B | 3.0B | -6.31 | 0.4 | ||||
BEAT | 47.4M | - | -3.24 | - | ||||
AMS | 18.7M | 21.3M | 35.03 | 0.88 |
LifeStance Health Group, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q2 | 2019Q4 |
Revenue | 6.7% | 280,603,000 | 262,895,000 | 259,578,000 | 252,589,000 | 229,360,000 | 217,560,000 | 209,527,000 | 203,095,000 | 189,995,000 | 173,835,000 | 160,549,000 | 143,132,000 | 118,121,000 | 101,982,000 | 45,453,000 | 111,661,000 | - |
Operating Expenses | -7.2% | 312,874,000 | 337,252,000 | 307,991,000 | 286,682,000 | 275,372,000 | 256,399,000 | 269,999,000 | 267,946,000 | 303,754,000 | 298,503,000 | 207,594,000 | 144,013,000 | 114,175,000 | 99,291,000 | 45,349,000 | 102,966,000 | - |
S&GA Expenses | -28.7% | 93,368,000 | 130,945,000 | 101,854,000 | 84,626,000 | 89,817,000 | 81,248,000 | 103,559,000 | 103,369,000 | 152,652,000 | 162,943,000 | 85,479,000 | 32,651,000 | 23,665,000 | 19,534,000 | 8,642,000 | 20,854,000 | - |
EBITDA Margin | 19.5% | -0.10 | -0.12 | -0.10 | -0.12 | -0.17 | -0.26 | -0.39 | -0.41 | -0.36 | -0.22 | -0.01 | 0.10 | 0.02 | - | - | - | - |
Interest Expenses | 1.0% | 5,532,000 | 5,477,000 | 5,119,000 | 5,092,000 | 5,165,000 | 4,189,000 | 7,133,000 | 3,441,000 | 3,602,000 | 3,503,000 | 23,174,000 | 8,632,000 | 7,129,000 | 6,421,000 | 5,562,000 | 3,020,000 | - |
Income Taxes | 140.5% | 6,643,000 | -16,385,000 | -6,542,000 | -4,037,000 | -7,060,000 | -4,353,000 | 923,000 | -6,676,000 | -10,608,000 | -8,751,000 | -3,788,000 | -2,761,000 | -2,948,000 | -1,074,000 | 1,370,000 | -2,319,000 | - |
Earnings Before Taxes | 50.9% | -38,316,000 | -77,968,000 | -52,020,000 | -38,279,000 | -53,716,000 | -42,206,000 | -67,804,000 | -69,004,000 | -118,638,000 | -129,203,000 | -73,821,000 | -11,443,000 | -7,067,000 | -4,368,000 | -5,712,000 | -27,264,000 | - |
EBT Margin | 11.5% | -0.20 | -0.22 | -0.19 | -0.22 | -0.27 | -0.36 | -0.50 | -0.54 | -0.50 | -0.37 | -0.18 | -0.07 | -0.12 | - | - | - | - |
Net Income | 27.0% | -44,959,000 | -61,583,000 | -45,478,000 | -34,242,000 | -46,656,000 | -37,853,000 | -68,727,000 | -62,328,000 | -108,030,000 | -120,452,000 | -70,033,000 | -8,682,000 | -5,489,000 | -3,294,000 | -4,342,000 | -24,945,000 | - |
Net Income Margin | 5.7% | -0.18 | -0.19 | -0.17 | -0.21 | -0.25 | -0.34 | -0.46 | -0.50 | -0.46 | -0.34 | -0.17 | -0.05 | -0.10 | - | - | - | - |
Free Cashflow | 115.3% | 5,381,000 | -35,151,000 | -12,015,000 | -15,619,000 | 25,534,000 | -9,366,000 | -18,032,000 | -24,602,000 | -8,042,000 | -38,221,000 | -37,637,000 | -1,172,000 | -6,449,000 | - | - | - | - |
Balance Sheet | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -3.0% | 2,110 | 2,175 | 2,171 | 2,159 | 2,174 | 1,980 | 1,969 | 1,958 | 1,927 | 1,915 | 1,914 | 1,570 |
Current Assets | -14.6% | 226 | 264 | 238 | 213 | 233 | 253 | 244 | 263 | 267 | 328 | 364 | 76.00 |
Cash Equivalents | 85.0% | 79.00 | 43.00 | 80.00 | 68.00 | 109 | 90.00 | 97.00 | 114 | 148 | 212 | 276 | 19.00 |
Net PPE | -1.0% | 188 | 190 | 193 | 194 | 194 | 193 | 191 | 171 | 152 | 115 | 92.00 | 59.00 |
Goodwill | 0.0% | 1,293 | 1,293 | 1,294 | 1,294 | 1,273 | 1,250 | 1,244 | 1,229 | 1,205 | 1,160 | 1,139 | 1,099 |
Liabilities | -5.4% | 681 | 720 | 676 | 653 | 655 | 448 | 437 | 416 | 382 | 370 | 370 | 537 |
Current Liabilities | -15.8% | 203 | 241 | 181 | 181 | 176 | 112 | 112 | 126 | 117 | 105 | 113 | 76.00 |
Long Term Debt | 12.8% | 280 | 248 | 249 | 225 | 225 | 212 | 203 | 177 | 157 | 157 | 157 | 363 |
LT Debt, Non Current | 12.8% | 280 | 248 | 249 | 225 | 225 | 212 | 203 | 177 | 157 | 157 | 157 | 363 |
Shareholder's Equity | -1.8% | 1,429 | 1,455 | 1,495 | 1,505 | 1,519 | 1,532 | 1,531 | 1,543 | 1,545 | 1,545 | 1,545 | 998 |
Retained Earnings | -6.3% | -760 | -715 | -654 | -608 | -572 | -525 | -488 | -419 | -357 | -249 | -128 | -13.12 |
Additional Paid-In Capital | 1.0% | 2,184 | 2,163 | 2,141 | 2,108 | 2,084 | 2,051 | 2,016 | 1,958 | 1,898 | 1,790 | 1,669 | 1.00 |
Shares Outstanding | 0.0% | 379 | 379 | 378 | 377 | 376 | 376 | 376 | 374 | 374 | 374 | 374 | - |
Float | - | - | - | 965 | - | - | - | 405 | - | - | - | 1,996 | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q2 | 2019Q4 |
Cashflow From Operations | 166.2% | 16,795 | -25,355 | -434 | -7,890 | 35,918 | 5,730 | 7,833 | 3,308 | 30,635 | -14,209 | -16,915 | 9,909 | 4,160 | 11,188 | -37,317 | 13,436 | - |
Share Based Compensation | -2.8% | 20,919 | 21,525 | 33,078 | 23,866 | 35,195 | 34,870 | 57,510 | 59,855 | 108,630 | 120,689 | 29,515 | 605 | 587 | 573 | 292 | - | - |
Cashflow From Investing | -16.5% | -11,414 | -9,796 | -11,581 | -27,549 | -30,296 | -20,272 | -38,038 | -50,855 | -79,562 | -43,585 | -59,094 | -11,835 | -144,644 | -20,234 | -671,213 | -25,078 | - |
Cashflow From Financing | 1767.8% | 30,838 | -1,849 | 23,326 | -4,888 | 12,663 | 8,192 | 12,901 | 13,508 | -15,167 | -6,270 | 312,702 | 22,591 | 134,245 | 20,310 | 722,334 | 35,385 | - |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
TOTAL REVENUE | $ 1,055,665 | $ 859,542 | $ 667,511 |
OPERATING EXPENSES | |||
Center costs, excluding depreciation and amortization shown separately below | 753,569 | 622,525 | 466,003 |
General and administrative expenses | 410,793 | 377,993 | 433,725 |
Depreciation and amortization | 80,437 | 69,198 | 54,136 |
Total operating expenses | 1,244,799 | 1,069,716 | 953,864 |
LOSS FROM OPERATIONS | (189,134) | (210,174) | (286,353) |
OTHER EXPENSE | |||
Gain (loss) on remeasurement of contingent consideration | 3,972 | (1,688) | (2,610) |
Transaction costs | (89) | (722) | (3,762) |
Interest expense, net | (21,220) | (19,928) | (38,911) |
Other expense | (112) | (218) | (1,469) |
Total other expense | (17,449) | (22,556) | (46,752) |
LOSS BEFORE INCOME TAXES | (206,583) | (232,730) | (333,105) |
INCOME TAX BENEFIT | 20,321 | 17,166 | 25,908 |
NET LOSS | (186,262) | (215,564) | (307,197) |
Accretion of Redeemable Class A units | 0 | 0 | (36,750) |
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS/MEMBERS | $ (186,262) | $ (215,564) | $ (343,947) |
NET LOSS PER SHARE, BASIC | $ (0.51) | $ (0.61) | $ (1.05) |
NET LOSS PER SHARE, DILUTED | $ (0.51) | $ (0.61) | $ (1.05) |
Weighted-average shares used to compute basic net loss per share | 367,457 | 355,278 | 327,523 |
Weighted-average shares used to compute diluted net loss per share | 367,457 | 355,278 | 327,523 |
Net Income (Loss) | $ (186,262) | $ (215,564) | $ (307,197) |
OTHER COMPREHENSIVE (LOSS) INCOME | |||
Unrealized (losses) gains on cash flow hedge, net of tax | (971) | 3,274 | 0 |
COMPREHENSIVE LOSS | $ (187,233) | $ (212,290) | $ (307,197) |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
CURRENT ASSETS | ||
Cash and cash equivalents | $ 78,824 | $ 108,621 |
Patient accounts receivable, net | 125,405 | 100,868 |
Prepaid expenses and other current assets | 21,502 | 23,734 |
Total current assets | 225,731 | 233,223 |
NONCURRENT ASSETS | ||
Property and equipment, net | 188,222 | 194,189 |
Right-of-use assets | 170,703 | 199,431 |
Intangible assets, net | 221,072 | 263,294 |
Goodwill | 1,293,346 | 1,272,939 |
Other noncurrent assets | 10,895 | 10,795 |
Total noncurrent assets | 1,884,238 | 1,940,648 |
Total assets | 2,109,969 | 2,173,871 |
CURRENT LIABILITIES | ||
Accounts payable | 7,051 | 12,285 |
Accrued payroll expenses | 102,478 | 75,650 |
Other accrued expenses | 35,012 | 30,428 |
Current portion of contingent consideration | 8,169 | 15,876 |
Operating lease liabilities, current | 46,475 | 38,824 |
Other current liabilities | 3,688 | 2,936 |
Total current liabilities | 202,873 | 175,999 |
NONCURRENT LIABILITIES | ||
Long-term debt, net | 280,285 | 225,079 |
Operating lease liabilities, noncurrent | 181,357 | 212,586 |
Deferred tax liability, net | 15,572 | 38,701 |
Other noncurrent liabilities | 952 | 2,783 |
Total noncurrent liabilities | 478,166 | 479,149 |
Total liabilities | 681,039 | 655,148 |
COMMITMENT AND CONTINGENCIES (see Note 13) | ||
STOCKHOLDERS' EQUITY | ||
Preferred stock - par value $0.01 per share; 25,000 shares authorized as of December 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022 | 0 | 0 |
Common stock - par value $0.01 per share; 800,000 shares authorized as of December 31, 2023 and December 31, 2022; 378,725 and 375,964 shares issued and outstanding as of December 31, 2023 and December 31, 2022,respectively | 3,789 | 3,761 |
Additional paid-in capital | 2,183,684 | 2,084,324 |
Accumulated other comprehensive income | 2,303 | 3,274 |
Accumulated deficit | (760,846) | (572,636) |
Total stockholders' equity | 1,428,930 | 1,518,723 |
Total liabilities and stockholders' equity | $ 2,109,969 | $ 2,173,871 |